Global Osteoarthritis Drugs Market- Snapshot

The global osteoarthritis drugs market is expected to reach a market value of about US$ 11,226.1 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period. Rise in R&D expenditure, increased prevalence of osteoarthritis across the globe, increased geriatric population, rise in awareness regarding degenerative bone diseases in developing countries, and rich pipeline of innovative treatment options are some factors that are expected to boost the global osteoarthritis drugs market during the forecast period. Moreover, increasing research and development activities in disease modifying drugs and surge in investment by key players in the clinical studies of advanced treatment options are expected to propel the global osteoarthritis drugs market during the forecast period. However, the high cost of advanced treatments and severe side-effects associated with certain injectable treatments are expected to hamper the osteoarthritis drugs market. 

global osteoarthritis drugs market

The global osteoarthritis drugs market has been segmented based on drug class, route of administration, and distribution channel. In terms of drug class, the global market has been classified into corticosteroids, NSAIDs & others, and viscosupplementation agents. The viscosupplementation agents segment dominates the global osteoarthritis drugs market, in terms of value, owing to its high cost. This segment is also expected to expand at a significant CAGR owing to its effectiveness in the treatment of knee osteoarthritis, increasing acceptance of viscosupplementation for the treatment of chronic pain associated with osteoarthritis, and long duration of pain relief provided by the treatment. Based on route of administration, the global osteoarthritis drugs market has been divided into oral, parenteral, and topical. The parenteral segment held a major share of the market in 2017. It is expected to maintain its leading position, in terms of market share, during the forecast period.

In terms of distribution channel, the global osteoarthritis drugs market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a major share of the market in 2017, followed by retail pharmacies. The hospital pharmacies segment is expected to maintain its market share during forecast period due to acceptance of advanced treatment options requiring hospitalization. The online pharmacies segment is projected to expand at a considerable CAGR during the forecast period, owing to easy availability of over-the-counter drugs at home at a discounted price.

In terms of geography, the global osteoarthritis drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global osteoarthritis drugs market owing to high acceptance of viscosupplementation agents in the U.S. and presence of major players in the region. According to the Centers for Disease Control and Prevention, one in every five adults in the U.S. has doctor-diagnosed arthritis. As the country's population ages, it is estimated that this number would increase to at least 67% by 2030. Rising incidence of osteoarthritis leading to disability, demanding advanced therapies and disease modifying drugs, is a major factor driving the market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to improving health care infrastructure, rising investments in research and development in countries such as China and India, and high acceptance of viscosupplementation agents in Japan. Furthermore, Japan is the second-largest market for viscosupplementation products after the U.S., which in turn is anticipated to further boost the market in Asia Pacific in the near future.

Major players operating in the global osteoarthritis drugs market include Horizon Pharma plc., Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Inc., Chugai Pharmaceutical Co., Limited, Alkem Laboratories, Flexion Therapeutics, Inc., and Zimmer Biomet Holdings, Inc. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.

Osteoarthritis Drugs Market to Rise Remarkably Owing to Increasing Adoption of 3D Printing Technique

Ascend in R&D consumption, expanded commonness of osteoarthritis across the globe, expanded geriatric populace, ascend in mindfulness in regards to degenerative bone illnesses in agricultural nations, and rich pipeline of creative treatment alternatives are a few factors that are relied upon to help the worldwide osteoarthritis drugs market during the conjecture time frame. Additionally, expanding innovative work exercises in sickness changing medications and flood in venture by central participants in the clinical investigations of cutting edge therapy choices are relied upon to impel the worldwide osteoarthritis drugs market during the conjecture time frame. Be that as it may, the significant expense of cutting edge medicines and serious results related with certain injectable medicines are required to hamper the osteoarthritis drugs market.

The developing attention to sicknesses like degenerative bone illness, expanding R&D, and developing geriatric populace are the excellent elements enlarging development of the market. The drug business is developing through an intense stage as a few key licenses have terminated. Then again, the business is additionally confronted with freedoms to decrease fabricating costs impressively, because of headways like 3D printing, a few rewarding reevaluating openings, and possibilities like Nano innovation. This is required to go about as an impetus for advancement in the business with a few firms previously increasing current standards with new medication improvements and crucial adjustments in measures.

Osteoarthritis (OA) is a pervasive sickness all around the world and it influences the older populace harshly. The condition is likewise perilous to numerous as it prompts disabled versatility prompting more possible mishaps and monetary limitations. Be that as it may, the current yield of osteoarthritis drugs just offers torment alleviation and help, yet not a lasting arrangement. Moreover, osteoarthritis drugs likewise neglect to stop infection movement. Henceforth, notwithstanding their absence of adequacy and outrageous significant expenses of viscosupplementation, the worldwide osteoarthritis drugs market keeps on developing. Also, the rising older populace all throughout the planet, and expanding reach of projects like Medicare in the US and privatized medical care bill as of late presented in Australia, the osteoarthritis drugs market will bring about a few new chances for development.

Global Osteoarthritis Drugs Market: Overview

This report analyzes the current and future scenario of the global osteoarthritis drugs market for the period 2018 to 2026. Rise in geriatric population, prevalence of obesity, high unmet medical needs, and rich pipeline are likely to be major drivers of the global osteoarthritis drugs market during the forecast period.

The global osteoarthritis drugs market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on drug class, route of administration, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the global osteoarthritis drugs market.

Global Osteoarthritis Drugs Market: Key Segments

Based on drug class, the global osteoarthritis drugs market has been segmented into corticosteroids, NSAIDs & others, and viscosupplementation agents. The segments have been analyzed based on available drugs used during the treatment of osteoarthritis, and cost-effectiveness. In terms of route of administration, the global osteoarthritis drugs market has been classified into oral, parenteral, and topical. Based on distribution channel, the global osteoarthritis drugs market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. Market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Global Osteoarthritis Drugs Market: Regional Outlook

In terms of region, the global osteoarthritis drugs market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report

The report also profiles major players operating in the global osteoarthritis drugs market based on various attributes, such as, company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include Horizon Pharma plc, Pfizer Inc., Sanofi, Anika Therapeutics Inc., Ferring B.V., Bioventus Inc, Chugai Pharmaceutical Co. Limited, Alkem Laboratories, Flexion Therapeutics Inc., and Zimmer Biomet Holdings Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

The global osteoarthritis drugs market has been segmented as below:

by Drug Class

  • Corticosteroids
  • NSAIDs & Others
  • Viscosupplementation Agents

by Route Of Administration

  • Oral
  • Parenteral
  • Topical

by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Osteoarthritis Drugs Market 

4. Market Overview
     4.1. Overview
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Osteoarthritis Drugs Market Analysis and Forecast, 2016–2026
            4.4.1. Global Osteoarthritis Drugs Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1.Disease Prevalence & Incidence Rate globally with key countries
     5.2.Regulatory Scenario by Region/globally
     5.3.Pipeline Analysis

6. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            6.3.1. Corticosteroids
            6.3.2. NSAIDs & others
            6.3.3. Viscosupplementation Agents 
     6.4. Global Osteoarthritis Drugs Market Attractiveness by Drug Class 

7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            7.3.1. Oral  
            7.3.2. Parenteral 
            7.3.3. Topical 
     7.4. Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration 

8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            8.3.1. Hospital pharmacies 
            8.3.2. Retail pharmacies 
            8.3.3. Online pharmacies 
     8.4. Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel 

9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Region
     9.1. Key Findings
     9.2. Global Osteoarthritis Drugs Market Value Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East & Africa 
     9.3. Global Osteoarthritis Drugs Market Attractiveness, by Region

10. North America Osteoarthritis Drugs Market Analysis and Forecast
     10.1. Introduction
     10.2. North America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            10.2.1.Corticosteroids
            10.2.2. NSAIDs & Others
            10.2.3.Viscosupplementation agents 
     10.3. North America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            10.3.1. Oral  
            10.3.2. Parenteral 
            10.3.3. Topical 
     10.4. North America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            10.4.1. Hospital pharmacies 
            10.4.2. Retail pharmacies 
            10.4.3. Online pharmacies 
     10.5. North America Osteoarthritis Drugs Market Value Forecast, by Country, 2016–2026
            10.5.1. US
            10.5.2. Canada 
     10.6. North America Osteoarthritis Drugs Market Attractiveness Analysis 
            10.6.1. By Drug Class 
            10.6.2. By Route of Administration 
            10.6.3. By Distribution Channel 
            10.6.4. By Country

11. Europe Osteoarthritis Drugs Market Analysis and Forecast
     11.1.Introduction
     11.2. Europe Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            11.2.1. Corticosteroids
            11.2.2. NSAIDs & Others
            11.2.3. Viscosupplementation agents 
     11.3. Europe Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            11.3.1. Oral  
            11.3.2. Parenteral 
            11.3.3. Topical 
     11.4. Europe Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            11.4.1. Hospital pharmacies 
            11.4.2. Retail pharmacies 
            11.4.3. Online pharmacies 
     11.5. Europe Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. France
            11.5.3. U.K.
            11.5.4. Italy
            11.5.5. Spain
            11.5.6. Rest of Europe
     11.6. Europe Osteoarthritis Drugs Market Attractiveness Analysis 
            11.6.1. By Drug Class 
            11.6.2. By Route of Administration 
            11.6.3. By Distribution Channel 
            11.6.4. By Country/Sub-region

12. Asia Pacific Osteoarthritis Drugs Market Analysis and Forecast
     12.1.Introduction
     12.2. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            12.2.1. Corticosteroids
            12.2.2. NSAIDs & Others
            12.2.3. Viscosupplementation agents 
     12.3. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            12.3.1. Oral  
            12.3.2. Parenteral 
            12.3.3. Topical 
     12.4. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            12.4.1. Hospital pharmacies 
            12.4.2. Retail pharmacies 
            12.4.3. Online pharmacies 
     12.5. Asia Pacific Osteoarthritis Drugs Market Value Forecast by Country/Sub-region, 2016–2026
            12.5.1. Japan
            12.5.2. China
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6. Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis 
            12.6.1. By Drug Class 
            12.6.2. By Route of Administration 
            12.6.3. By Distribution Channel 
            12.6.4. By Country/Sub-region

13. Latin America Osteoarthritis Drugs Market Analysis and Forecast
     13.1.Introduction
     13.2. Latin America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            13.2.1. Corticosteroids
            13.2.2. NSAIDs & Others
            13.2.3. Viscosupplementation agents 
     13.3. Latin America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            13.3.1. Oral  
            13.3.2. Parenteral 
            13.3.3. Topical 
     13.4. Latin America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            13.4.1. Hospital pharmacies 
            13.4.2. Retail pharmacies 
            13.4.3. Online pharmacies 
     13.5. Latin America Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Latin America Osteoarthritis Drugs Market Attractiveness Analysis 
            13.6.1. By Drug Class 
            13.6.2. By Route of Administration 
            13.6.3. By Distribution Channel 
            13.6.4. By Country/Sub-region

14. Middle East & Africa Osteoarthritis Drugs Market Analysis and Forecast
     14.1.Introduction
     14.2. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            14.2.1. Corticosteroids
            14.2.2. NSAIDs & Others
            14.2.3. Viscosupplementation agents 
     14.3. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            14.3.1. Oral  
            14.3.2. Parenteral 
            14.3.3. Topical 
     14.4. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            14.4.1. Hospital pharmacies 
            14.4.2. Retail pharmacies 
            14.4.3. Online pharmacies 
     14.5. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Country/Sub-regions, 2016–2026
            14.5.1. GCC Countries
            14.5.2. Israel
            14.5.3. South Africa
            14.5.4. Rest of MEA
     14.6. Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis 
            14.6.1. By Drug Class 
            14.6.2. By Route of Administration 
            14.6.3. By Distribution Channel 
            14.6.4. By Country

15. Competition Landscape
     15.1. Global Osteoarthritis Drugs Market Player – Competition Matrix (by Tier and Size of companies)
     15.2. Global Osteoarthritis Drugs Market Share Analysis, by Company (2016)
     15.3. Company Profiles
            15.3.1. Horizon Pharma plc. 
                     15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.1.2. Product Portfolio
                     15.3.1.3. SWOT Analysis
                     15.3.1.4. Financial Overview
                     15.3.1.5. Strategic Overview
            15.3.2. Pfizer Inc.
                     15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.2.2. Product Portfolio
                     15.3.2.3. SWOT Analysis
                     15.3.2.4. Financial Overview
                     15.3.2.5. Strategic Overview
            15.3.3. Sanofi 
                     15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.3.2. Product Portfolio
                     15.3.3.3. SWOT Analysis
                     15.3.3.4. Financial Overview
                     15.3.3.5. Strategic Overview
            15.3.4. Anika Therapeutics, Inc.  
                     15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.4.2. Product Portfolio
                     15.3.4.3. SWOT Analysis
                     15.3.4.4. Financial Overview
                     15.3.4.5. Strategic Overview
            15.3.5. Ferring B.V.
                     15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.5.2. Product Portfolio
                     15.3.5.3. SWOT Analysis
                     15.3.5.4. Financial Overview
                     15.3.5.5. Strategic Overview
            15.3.6. Bioventus, Inc. 
                     15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.6.2. Product Portfolio
                     15.3.6.3. SWOT Analysis
                     15.3.6.4. Financial Overview
                     15.3.6.5. Strategic Overview
            15.3.7. Chugai Pharmaceutical Industries Limited  
                     15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.7.2. Product Portfolio
                     15.3.7.3. SWOT Analysis
                     15.3.7.4. Financial Overview
                     15.3.7.5. Strategic Overview
            15.3.8. Alkem Laboratories
                     15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.8.2. Product Portfolio
                     15.3.8.3. SWOT Analysis
                     15.3.8.4. Financial Overview
                     15.3.8.5. Strategic Overview
            15.3.9. Flexion Therapeutics, Inc.  
                     15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.9.2. Product Portfolio
                     15.3.9.3. SWOT Analysis
                     15.3.9.4. Financial Overview
                     15.3.9.5. Strategic Overview
            15.3.10. Zimmer Biomet Holdings, Inc.
                     15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.10.2. Product Portfolio
                     15.3.10.3. SWOT Analysis
                     15.3.10.4. Financial Overview
                     15.3.10.5. Strategic Overview

List of Tables

Table 01: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 03: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 04: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 06: North America Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 07: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 08: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 09: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 10: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 11: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 12: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 13: Asia Pacific Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 14: Asia Pacific Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 15: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 18: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 19: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 20: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 23: Middle East & Africa Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 24: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

 

 

List of Figures

Figure 01: Global Osteoarthritis Drugs Market Snapshot
Figure 02: Global Fluid Management Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 03: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, 2016?2026
Figure 04: Global Osteoarthritis Drugs Market Value Share, by Drug Class (2017)
Figure 05: Global Osteoarthritis Drugs Market Value Share, by Route of Administration (2017)
Figure 06: Global Osteoarthritis Drugs Market Value Share, by Distribution Channel (2017)
Figure 07: Global Osteoarthritis Drugs Market Value Share, by Region (2017)
Figure 08: Global Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 09: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids
Figure 10: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Others
Figure 11: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Viscosupplementation Agents
Figure 12: Global Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 13: Global Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 14: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2016–2026
Figure 15: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2016–2026
Figure 16: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2016–2026
Figure 17: Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 18: Global Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 19: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016–2026
Figure 20: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016–2026
Figure 21: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2016–2026
Figure 22: Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 23: Global Osteoarthritis Drugs Market Value Share Analysis, by Region 2017 and 2026
Figure 24: Global Osteoarthritis Drugs Market Attractiveness, by Region, 2018–2026
Figure 25: North America Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 26: North America Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 27: North America Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 28: North America Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 29: North America Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 30: North America Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 31: North America Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 32: North America Osteoarthritis Drugs Market Value Share (%), by Country, 2017 and 2026
Figure 33: North America Osteoarthritis Drugs Market Attractiveness, by Country, 2018–2026
Figure 34: Europe Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 35: Europe Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 36: Europe Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 37: Europe Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 38: Europe Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 39: Europe Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 40: Europe Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 41: Europe Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 42: Europe Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 43: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 44: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 45: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 46: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 47: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 48: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 49: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 50: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 51: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 52: Latin America Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 53: Latin America Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 54: Latin America Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 55: Latin America Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 56: Latin America Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 57: Latin America Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 58: Latin America Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 59: Latin America Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 60: Latin America Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 61: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 62: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 63: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 64: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 65: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 66: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 67: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 68: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 69: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 70: Global Osteoarthritis Drugs Market Share Analysis, by Company (2017)
Figure 71: Horizon Pharma plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 72: Horizon Pharma plc. Breakdown of Net Sales, by Region, 2017
Figure 73: Horizon Pharma plc. Breakdown of Net Sales, by Drug, 2017
Figure 74: Horizon Pharma plc. Research & Development Cost (US$ Mn), 2015–2017
Figure 75: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 76: Pfizer Inc. R&D Expenses (US$ Mn), 2014–2017
Figure 77: Sanofi Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 78: Sanofi Breakdown of Net Sales, by Region, 2017
Figure 79: Sanofi Breakdown of Net Sales, by Business Segment, 2017
Figure 80: Sanofi Research & Development Cost, 2015–2017 (US$ Mn)
Figure 81: Anika Therapeutics, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 82: Anika Therapeutics, Inc. Breakdown of Net Sales, by Region, 2017
Figure 83: Anika Therapeutics, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 84: Anika Therapeutics, Inc. Research & Development Cost, 2015–2017 (US$ Mn)
Figure 85: Chugai Pharmaceutical Co., Limited. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 86: Chugai Pharmaceutical Co., Limited. Breakdown of Net Sales, by Region, 2017
Figure 87: Chugai Pharmaceutical Co., Limited. Breakdown of Net Sales, by Business Segment, 2017
Figure 88: Chugai Pharmaceutical Co., Limited. Research & Development Cost (US$ Mn), 2015–2017
Figure 89: Alkem Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 90: Alkem Laboratories Breakdown of Net Sales, by Region, 2017
Figure 91: Alkem Laboratories Breakdown of Net Sales, by Business Segment, 2017
Figure 92:  Alkem Laboratories Research & Development Cost (US$ Mn), 2015–2017
Figure 93: Zimmer Biomet Holdings, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 94:  Zimmer Biomet Holdings, Inc. Breakdown of Net Sales, by Region, 2017
Figure 95:  Zimmer Biomet Holdings, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 96:  Zimmer Biomet Holdings, Inc. Research & Development Cost (US$ Mn), 2015–2017

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Osteoarthritis Drugs Market